Local consolidative therapy does not improve survival after dual immunotherapy in metastatic NSCLC

Phase III TAISHAN-302 trial shows Tam-Peli significantly improves survival in relapsed small-cell lung cancer

Sacituzumab govitecan plus pembrolizumab does not meet primary endpoints in first-line PD-L1-high metastatic NSCLC

Shapeshifting plant roots rely on a balance of anatomy, metabolism, and microbes to maximize survival